AstraZeneca has been engulfed by concerns and criticism of its COVID-19 vaccine collaboration with Oxford University in recent weeks, but CEO Pascal Soriot maintained calm at the eye of the storm during the company’s Q4 and full year results.
Incomplete trial data has led many European countries to limit the vaccine’s use to under 65s, despite a European Medicines Agency approval two weeks ago
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?